Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 6/20 | 0.58 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.47 |
| ▸ | F11 | P03951 | 2/20 | 0.44 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28327818 | 0.92 | LPL (0.58) | LPLLIPGSIGMAR1F11KCNJ1 | |
| SCHEMBL5256283 | 0.90 | LPL (0.60) | LPLLIPGSIGMAR1F11KCNJ1 | |
| SCHEMBL1354431 | 0.90 | LPL (0.59) | LPLLIPGSIGMAR1CYP1A2F11 | |
| SCHEMBL28327797 | 0.88 | LPL (0.58) | LPLLIPGSIGMAR1CYP1A2F11 | |
| SCHEMBL586178 | 0.87 | LPL (0.56) | LPLLIPGSIGMAR1F11ESR2 | |
| SCHEMBL429722 | 0.87 | LMNA (0.53) | LPLLIPGF11ESR2 | |
| SCHEMBL28621374 | 0.86 | LIPG (0.52) | LPLLIPGSIGMAR1F11KCNJ1 | |
| Hydrochloric Acid SCHEMBL27248303 | 0.86 | LPL (0.55) | LPLLIPGSIGMAR1F11ESR2 | |
| SCHEMBL24265977 | 0.85 | LIPG (0.54) | LPLLIPGSIGMAR1CYP2D6F11 | |
| SCHEMBL28327814 | 0.84 | LIPG (0.50) | LPLLIPGF11KCNJ1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092032-A1 | DEOXYCYTIDINE KINASE INHIBITORS | INSTITUT JEAN PAOLI & IRENE CALMETTES CENTRE REGIONAL DE LUTTE CONTRE LE CANCER (FR) | 2025-03-20 | — | — | US | disclosed |
| CN-110506044-B | BRD4 inhibitor and preparation and application thereof | 中国科学院上海药物研究所 | 2022-07-05 | — | — | CN | disclosed |
| CN-108368083-B | Heteroaryl compounds and their use as therapeutic agents | 东亚首希控股股份有限公司 | 2022-02-01 | — | — | CN | disclosed |
| CN-112243439-A | Pyrrolo [2,3-B ] pyridines or pyrrolo [2,3-B ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2021-01-19 | — | — | CN | disclosed |
| CN-110506044-A | A kind of BRD4 inhibitor and its preparation and application | SHANGHAI INST MATERIA MEDICA CAS | 2019-11-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092032-A1 | DEOXYCYTIDINE KINASE INHIBITORS | DCK, DTYMK, TYMP | LPL 3336/4885LIPG 2053/4885SIGMAR1 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.